Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05528172 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery
A Phase 3 study, sponsored by Kowa Research Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 331
- Enrollment target
NCT05528172 is a Phase 3 study that has completed, run by Kowa Research Institute. The registered enrollment target is 331 participants.
The verdict
NCT05528172, a Phase 3 study, has completed, sponsored by Kowa Research Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 331 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of K-321 in subjects after cataract surgery
Interventions
- DRUG Placebo
- DRUG Ripasudil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 331 participants |
| Start Date | 2022-08-04 |
| Est. Completion | 2023-06-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05528172
The ClinicalTrials.gov registry entry for NCT05528172 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 331 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kowa Research Institute, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05528172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05528172 about?
NCT05528172 is a clinical study titled "A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery". The purpose of this study is to assess the safety and efficacy of K-321 in subjects after cataract surgery
What is the current status of trial NCT05528172?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 331 participants. The study started on 2022-08-04. Estimated completion is 2023-06-22.
What interventions are being tested in trial NCT05528172?
The interventions under investigation include: Placebo (DRUG), Ripasudil (DRUG).
Who is sponsoring clinical trial NCT05528172?
This trial is sponsored by Kowa Research Institute, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.